FDA grants Orphan Drug Designation to zenocutuzumab (Zeno) for treatment of pancreatic cancer

Zeno is a first in class bispecific antibody that binds to HER2 and HER3 receptors, to block interaction of HER3 with its ligand, neuregulin 1. It has shown promising early clinical responses in patients with previously treated pancreatic cancer harboring NRG1 gene fusions.


Biospace Inc.